Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan

Annals of the Rheumatic Diseases

Volumn 78, Issue 10, 2019, Pages 1305-1319

  Takeuchi, Tsutomu ^a   Tanaka, Yoshiya ^b   Tanaka, Sakae ^c   Kawakami, Atsushi ^d   Iwasaki, Manabu ^e   Katayama, Kou ^f   Rokuda, Mitsuhiro ^g   Izutsu, Hiroyuki ^g   Ushijima, Satoshi ^g   Kaneko, Yuichiro ^g   Shiomi, Teruaki ^g   Yamada, Emi ^g   Van Der Heijde, Désirée ^h  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

^f Katayama Orthopedic Rheumatology Clinic   (Japan)

^g ASTELLAS PHARMA INC   (Japan)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

DAS28; disease activity; methotrexate; rheumatoid arthritis; treatment

Indexed keywords

METHOTREXATE; PEFICITINIB; PLACEBO; ADAMANTANE; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; JANUS KINASE INHIBITOR; NICOTINAMIDE;

ADULT; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOLOGICAL PARAMETERS; HERPES ZOSTER; HUMAN; INCIDENCE; JAPAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; SUICIDE; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; DRUG SUBSTITUTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADAMANTANE; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG SUBSTITUTION; FEMALE; HERPES ZOSTER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTIONS; JANUS KINASE INHIBITORS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; NIACINAMIDE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 85070074782     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2019-215164     Document Type: Article

References (41)

1. Kiadaliri AA, Felson DT, Neogi T, et al. Brief report: rheumatoid arthritis as the underlying cause of death in Thirty-One countries, 1987-2011: trend analysis of World Health Organization mortality database. Arthritis Rheumatol 2017;69:1560-5.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
3. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care 2007;13 suppl 9:s237-51.
4. Mcinnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
5. Taylor PC, Moore A, Vasilescu R, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 2016;36:685-95.
6. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
7. Smolen JS, Landewé R, Bijlsma J, et al. Eular recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
8. Smolen JS, Aletaha D, Bijlsma JWJ, et al. Treating rheumatoid arthritis to target: recommendations of an international Task Force. Ann Rheum Dis 2010;69:631-7.
9. Zampeli E, Vlachoyiannopoulos PG, Tzioufas AG. Treatment of rheumatoid arthritis: unraveling the conundrum. J Autoimmun 2015;65:1-18.
10. Malemud CJ. The role of the JaK/sTaT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis 2018;10:117-27.
11. Tanaka Y, Iwata S, Yamaoka K. JaK and sYK: emerging their relevance to the treatment of infammatory diseases. Infamm Regen 2011;31:237-44.
12. Tanaka Y, Maeshima Y, Yamaoka K. in vitro and in vivo analysis of a JaK inhibitor in rheumatoid arthritis. Ann Rheum Dis 2012;71(suppl 2):i70-4.
13. Tanaka Y, Yamaoka K. JaK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol 2013;23:415-24.
14. Norman P. Selective JaK inhibitors in development for rheumatoid arthritis. Exp Opin Investig Drugs 2014;23:1067-77.
15. Ito M, Yamazaki S, Yamagami K, et al. A novel JaK inhibitor, pefcitinib, demonstrates potent effcacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci 2017;133:25-33.
16. Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 2016;32:29-33.
17. Takeuchi T, Tanaka Y, Iwasaki M, et al. Effcacy and safety of the oral Janus kinase inhibitor pefcitinib (asP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase iib study. Ann Rheum Dis 2016;75:1057-64.
18. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93:385-95.
19. Genovese MC, Greenwald M, Codding C, et al. Pefcitinib, a JaK inhibitor, in combination with limited conventional synthetic disease-modifying antirheumatic drugs in the treatment of moderate-to-severe rheumatoid arthritis. Arthritis Rheumatol 2017;69:932-42.
20. Kivitz AJ, Gutierrez-Ureña SR, Poiley J, et al. Pefcitinib, a JaK inhibitor, in the treatment of moderate-to-severe rheumatoid arthritis in patients with an inadequate response to methotrexate. Arthritis Rheumatol 2017;69:709-19.
21. Arnett FC, Edworthy SM, Bloch DA, et al. The american rheumatism association 1987 revised criteria for the classifcation of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
22. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classifcation criteria: an american College of Rheumatology/european league against rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
23. Hochberg MC, Chang RW, Dwosh I, et al. The american College of rheumatology 1991 revised criteria for the classifcation of global functional status in rheumatoid arthritis. Arthritis Rheum 1992;35:498-502.
24. Felson D T, Anderson JJ, Boers M, et al. American College of rheumatology. Preliminary defnition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
25. Van der Heijde D. How to read radiographs according to the sharp/van Der Heijde method. J Rheumatol 2000;27:261-3.
26. Fransen J, Van Riel PLCM. The disease activity score and the eUlaR response criteria. Clin Exp Rheumatol 2005;23(5 suppl 39):s93-9.
27. Bruce B, Fries J F. The stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
28. Fries J F, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
29. Dougados M, Van der Heijde D, Chen Y-C, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMaRDs: results from the Ra-BUilD study. Ann Rheum Dis 2017;76:88-95.
30. Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66:2675-84.
31. Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther 2016;18:1-12.
32. Tanaka Y, Takeuchi T, Yamanaka H, et al. Effcacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 2015;25:514-21.
33. Smolen J, Genovese M, Takeuchi T, et al. Thu0166 safety Profle of Baricitinib in Patients with active Ra: an integrated analysis: Table 1. Ann Rheum Dis 2016;75(suppl 2):243.2-4.
34. Scott IC, Hider SL, Scott DL. Thromboembolism with Janus kinase (JaK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf 2018;41:645-53.
35. Takahashi C, Kaneko Y, Okano Y, et al. Association of erythrocyte methotrexate-polyglutamate levels with the effcacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a 76-week prospective study. RMD Open 2017;3:e000363.
36. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an il-6 inhibitor (saMURai): evidence of clinical and radiographic beneft from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7.
37. Takeuchi T, Miyasaka N, Zang C, et al. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis. Mod Rheumatol 2013;23:623-33.
38. Yamamoto K, Takeuchi T, Yamanaka H, et al. Effcacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HiKaRi randomized, placebo-controlled trial. Mod Rheumatol 2014;24:552-60.
39. Breedveld FC, Weisman MH, Kavanaugh A F, et al. The premier study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus Methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
40. Atsumi T, Yamamoto K, Takeuchi T, et al. The frst double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPeRa, shows inhibition of radiographic progression. Ann Rheum Dis 2016;75:75-83.
41. Abstract. RaJ3. effcacy and safety of the novel oral Janus kinase inhibitor, Pefcitinib (asP015K), in a phase 3, double-blind, placebo-controlled, randomized study of patients with Ra who had an inadequate response to DMaRDs. ACR/ARHP 2018.